Geneoscopy, Inc.
Geneoscopy is dedicated to transforming gastrointestinal health through innovative, noninvasive diagnostic tests. Founded by siblings Andrew and Erica Barnell, the company leverages proprietary stool-derived eukaryotic RNA (seRNA) technology to develop tests for colorectal cancer and other GI diseases. With FDA-approved ColoSense™ test and strategic partnerships, Geneoscopy aims to improve early detection, treatment, and monitoring of gastrointestinal conditions, ultimately enhancing patient outcomes and health equity.
Industries
Nr. of Employees
medium (51-250)
Geneoscopy, Inc.
2220 Welsch Industrial Ct, St. Louis, MO 63146
Patents
Products
Noninvasive multi-target stool RNA colorectal cancer screening test
A laboratory-performed stool-based assay that qualitatively detects colorectal neoplasia-associated RNA markers and occult hemoglobin to screen average-risk adults for colorectal cancer and advanced precancerous lesions.
Noninvasive multi-target stool RNA colorectal cancer screening test
A laboratory-performed stool-based assay that qualitatively detects colorectal neoplasia-associated RNA markers and occult hemoglobin to screen average-risk adults for colorectal cancer and advanced precancerous lesions.
Services
Provision of a single-site clinical laboratory service performing stool-derived RNA and occult hemoglobin testing for colorectal cancer screening in average-risk adults.
Execution of analytical validation studies and preparation/support of regulatory submissions to health authorities for diagnostic assays.
Integration of at-home stool collection into clinical studies, provision of sample processing and molecular readouts, and support for companion diagnostic or therapeutic monitoring tool development.
Application of machine-learning models to transcriptomic data from stool to produce classifiers for disease detection, activity monitoring, and severity stratification.
Access to a curated stool sample biobank and associated molecular characterization to support R&D, validation studies, and exploratory research.
Provision of a single-site clinical laboratory service performing stool-derived RNA and occult hemoglobin testing for colorectal cancer screening in average-risk adults.
Execution of analytical validation studies and preparation/support of regulatory submissions to health authorities for diagnostic assays.
Integration of at-home stool collection into clinical studies, provision of sample processing and molecular readouts, and support for companion diagnostic or therapeutic monitoring tool development.
Application of machine-learning models to transcriptomic data from stool to produce classifiers for disease detection, activity monitoring, and severity stratification.
Access to a curated stool sample biobank and associated molecular characterization to support R&D, validation studies, and exploratory research.
Expertise Areas
- RNA-based stool diagnostics
- Clinical trial management for diagnostic assays
- Analytical assay validation and performance characterization
- Clinical laboratory operations (CLIA/CAP) and state permitting
Key Technologies
- Stool-derived eukaryotic RNA analysis
- At-home stool collection kits
- Next-generation sequencing (NGS)
- Droplet digital PCR (ddPCR)
News & Updates
Invalidating all 20 claims of Exact Sciences’ ’781 Patent, strengthening Geneoscopy’s intellectual property rights.
A study published in Clinical Gastroenterology and Hepatology confirms the real-world screening impact of ColoSense®.
The latest NCCN guidelines now include Geneoscopy’s ColoSense® test for colorectal cancer screening.
The company raised $105 million to power the next generation of GI diagnostic tests.
Amit Bhalla joins to support strategic growth and commercialization efforts.
Andrew Barnell will discuss the company’s market opportunity and technology advancements.
Invalidating all 20 claims of Exact Sciences’ ’781 Patent, strengthening Geneoscopy’s intellectual property rights.
A study published in Clinical Gastroenterology and Hepatology confirms the real-world screening impact of ColoSense®.
The latest NCCN guidelines now include Geneoscopy’s ColoSense® test for colorectal cancer screening.
The company raised $105 million to power the next generation of GI diagnostic tests.
Amit Bhalla joins to support strategic growth and commercialization efforts.
Andrew Barnell will discuss the company’s market opportunity and technology advancements.